Art. -Nr.: HY-18258

Berberine chloride

Name: Berberine chloride
Brand: MedChemExpress
SKU: HY-18258
Price: 30.00 USD
Availability: InStock
Rating: 5 (83 reviews)

(Synonyms: Natural Yellow 18 chloride)

83 Cited Publications

Kundenbewertung

Based on 83 publication(s) in Google Scholar

Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.92%
CAS. Nr.: 633-65-8
Formel: C₂₀H₁₈ClNO₄
Molecular Weight:371.81

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Berberine chloride Chemical Structure

CAS. Nr.: 633-65-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (83)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (1)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

ROS^[1]
DNA topoisomerase^[1]

Alle Topoisomerase Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	21.84 μM Compound: Berberine	Cytotoxicity against mouse 3T3L1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Cytotoxicity against mouse 3T3L1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 28818460]
A10	GI₅₀	101.62 μM Compound: 2	Growth inhibition against rat A10 cells after 72 hrs by MTT assay Growth inhibition against rat A10 cells after 72 hrs by MTT assay	[PMID: 21401114]
A2780	IC₅₀	>50 μM Compound: BBR; 1	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A549	IC₅₀	>50 μM Compound: BBR	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
A549	IC₅₀	>50 μM Compound: BBR; 1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A549	IC₅₀	6.27 μM Compound: 10	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20594848]
Bel-7402	IC₅₀	16.28 μM Compound: 1, Berberine	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
BGC-823	IC₅₀	7.04 μM Compound: 1, Berberine	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
BHK-21	CC₅₀	>100 μM Compound: 190	Cytotoxicity against BHK21 cells in presence of ATP by Celltiter-Glo assay Cytotoxicity against BHK21 cells in presence of ATP by Celltiter-Glo assay	[PMID: 28689975]
C6	IC₅₀	>20 μM Compound: 1	Cytotoxicity against rat C6 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	10.1039/C4MD00264D
CCRF S-180	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against mouse CCRF S-180 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against mouse CCRF S-180 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
CCRF-CEM	CC₅₀	2.09 μM Compound: 1	Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay	[PMID: 21295891]
CCRF-CEM	EC₅₀	0.13 μM Compound: 1	Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA	[PMID: 21295891]
CHO-K1	IC₅₀	336 μM Compound: BBR	Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32688201]
DU-145	IC₅₀	>20 μM Compound: BBR	Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
ECa-109 cell line	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human Eca-109 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human Eca-109 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
G-402	GI₅₀	11.87 μM Compound: 2	Growth inhibition against human G402 cells after 48 hrs by MTT assay Growth inhibition against human G402 cells after 48 hrs by MTT assay	[PMID: 21401114]
HCT-116	IC₅₀	>10 μM Compound: BBR	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
HCT-116	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
HCT-116	IC₅₀	39.95 μM Compound: Berberine Chloride	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28359045]
HCT-116	IC₅₀	83.09 μM Compound: Ber	Inhibition of cell proliferation of human HCT116 cells incubated for 15 hrs by MTT assay Inhibition of cell proliferation of human HCT116 cells incubated for 15 hrs by MTT assay	[PMID: 32391701]
HCT-15	IC₅₀	16.59 μM Compound: 10	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20594848]
HCT-8	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
HeLa	IC₅₀	12.08 μg/mL Compound: Berberine	Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 31821990]
HeLa	IC₅₀	138.4 g/mL Compound: Berberine, I	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 18295494]
HeLa 229	IC₅₀	42.93 μM Compound: Berberine	Cytotoxicity against human HeLa 229 cells measured after 48 hrs by MTT assay Cytotoxicity against human HeLa 229 cells measured after 48 hrs by MTT assay	[PMID: 31821990]
Hep 3B2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
Hepatocyte	IC₅₀	26.5 μg/mL Compound: Berberine, I	Cytotoxicity against Sprague-Dawley rat primary hepatocytes after 24 hrs by MTT assay Cytotoxicity against Sprague-Dawley rat primary hepatocytes after 24 hrs by MTT assay	[PMID: 18295494]
HepG2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against cisplatin-resistant human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against cisplatin-resistant human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
HepG2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
HepG2	IC₅₀	>50 μM Compound: BBR	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
HepG2	IC₅₀	>50 μM Compound: BBR; 1	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HepG2	IC₅₀	11.22 μM Compound: 1, Berberine	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23182088]
HepG2	IC₅₀	13.8 μM Compound: BER	Down regulation of PCSK9 mRNA expression in human HepG2 cells incubated for 24 hrs by SYBR green dye-based qRT-PCR analysis Down regulation of PCSK9 mRNA expression in human HepG2 cells incubated for 24 hrs by SYBR green dye-based qRT-PCR analysis	[PMID: 33567826]
HepG2	IC₅₀	146.2 g/mL Compound: Berberine, I	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 18295494]
HepG2	IC₅₀	46.9 μg/mL Compound: 1; BBR	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27561717]
HepG2	IC₅₀	49.01 μM Compound: Berberine Chloride	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28359045]
HepG2	IC₅₀	53.91 μg/mL Compound: Berberine chloride	Cytotoxicity against human HepG2 cells after 12 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells after 12 hrs by CCK-8 assay	[PMID: 31057739]
HepG2	IC₅₀	8.32 μM Compound: 1, Berberine	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23182088]
HL-60	IC₅₀	27.42 μM Compound: Berberine Chloride	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28359045]
HL-60	IC₅₀	5.83 μM Compound: 1, Berberine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
HT-29	IC₅₀	>10 μM Compound: BBR	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
HT-29	IC₅₀	>20 μM Compound: 1, Berberine	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 23182088]
HT-29	IC₅₀	>50 μM Compound: BBR; 1	Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HT-29	IC₅₀	8.45 μM Compound: 1, Berberine	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 23182088]
Huh-7	CC₅₀	>100 μM Compound: GNF-Pf-4545	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Huh-7	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
HUVEC	IC₅₀	18.34 μM Compound: Berberine	Cytotoxicity against human HUVEC cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HUVEC cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
KB	IC₅₀	6.03 μM Compound: 1, Berberine	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
KB	IC₅₀	7.32 μM Compound: Berberine chloride	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 11141105]
KM12C	IC₅₀	76.34 μM Compound: Ber	Inhibition of cell proliferation of human KM12C cells incubated for 15 hrs by MTT assay Inhibition of cell proliferation of human KM12C cells incubated for 15 hrs by MTT assay	[PMID: 32391701]
L02	IC₅₀	>50 μM Compound: BBR	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
L02	IC₅₀	>50 μM Compound: BBR; 1	Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
L02	IC₅₀	71.55 μM Compound: Berberine Chloride	Cytotoxicity against human LO2 cells after 72 hrs by MTT assay Cytotoxicity against human LO2 cells after 72 hrs by MTT assay	[PMID: 28359045]
LNCaP	IC₅₀	>50 μM Compound: Berberine chloride	Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
LS174T	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human LS174T cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human LS174T cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
LX-2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human LX2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human LX2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
MCF-10A	IC₅₀	>50 μM Compound: Berberine chloride	Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
MCF7	IC₅₀	>50 μM Compound: Berberine chloride	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
MCF7	IC₅₀	75 μM Compound: berberine	Inhibition of telomerase expressed in MCF7 cells by TRAP assay Inhibition of telomerase expressed in MCF7 cells by TRAP assay	[PMID: 17574421]
MDA-MB-231	IC₅₀	20.6 μM Compound: BBR	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
MDCK	CC₅₀	70.22 μg/mL Compound: Ber	Cytotoxicity against MDCK cells incubated for 48 hrs assessed as reduction in cell viability by SRB assay Cytotoxicity against MDCK cells incubated for 48 hrs assessed as reduction in cell viability by SRB assay	[PMID: 28958846]
MKN-28	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human MKN-28 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human MKN-28 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
MRC5	CC₅₀	74 μM Compound: 1	Cytotoxicity against MRC5 cells Cytotoxicity against MRC5 cells	[PMID: 17239594]
MRC5	IC₅₀	0.68 μM Compound: 1	Antiviral activity against HCMV in MRC5 cells by plaque reduction assay Antiviral activity against HCMV in MRC5 cells by plaque reduction assay	[PMID: 17239594]
NCI-H446	IC₅₀	>50 μM Compound: BBR	Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
PANC-1	IC₅₀	>50 μM Compound: BBR; 1	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
PANC-1	IC₅₀	>50 μM Compound: Berberine chloride	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
PC-12	CC₅₀	>150 μM Compound: 1	Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay	[PMID: 33611188]
PC-3	IC₅₀	14.39 μM Compound: BBR	Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
PC-3	IC₅₀	31.72 μM Compound: BBR; 1	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
RAW264.7	IC₅₀	>30 μM Compound: 6	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 22024033]
RAW264.7	IC₅₀	6.9 μM Compound: Berberine	Inhibition of PCSK9 mRNA level in mouse RAW264.7 cells by qRT-PCR assay Inhibition of PCSK9 mRNA level in mouse RAW264.7 cells by qRT-PCR assay	[PMID: 30698432]
SGC-7901	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
SK-HEP1	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
SK-MEL-2	IC₅₀	13.76 μM Compound: 10	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 20594848]
SK-OV-3	IC₅₀	16.44 μM Compound: 10	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 20594848]
SMMC-7721	IC₅₀	18.34 μM Compound: Berberine	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	25.94 μM Compound: Berberine Chloride	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 28359045]
SW1990	IC₅₀	18.34 μM Compound: Berberine	Cytotoxicity against human SW1990 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW1990 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW-620	IC₅₀	126.2 μM Compound: Ber	Inhibition of cell proliferation of human SW620 cells incubated for 15 hrs by MTT assay Inhibition of cell proliferation of human SW620 cells incubated for 15 hrs by MTT assay	[PMID: 32391701]
SW-620	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
THP-1	IC₅₀	5.1 μM Compound: BBR	Inhibition of LPS + nigericin-induced IL-1beta secretion in PMA-differentiated human THP-1 cells incubated for 1 to 24 hrs by Immunoblot analysis Inhibition of LPS + nigericin-induced IL-1beta secretion in PMA-differentiated human THP-1 cells incubated for 1 to 24 hrs by Immunoblot analysis	[PMID: 33440945]
U-87MG ATCC	IC₅₀	>20 μM Compound: 1	Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	10.1039/C4MD00264D
U-937	IC₅₀	35 μM Compound: Berberine chloride	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	10.1039/C0MD00241K
Vero	IC₅₀	71.14 μg/mL Compound: Berberine	Cytotoxicity against African green monkey Vero cells measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells measured after 48 hrs by MTT assay	[PMID: 31821990]
Vero C1008	CC₅₀	221 μM Compound: 49	Cytotoxicity against African green monkey Vero E6 cells measured up to 24 to 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells measured up to 24 to 72 hrs by MTT assay	[PMID: 31549836]
VSMC	GI₅₀	95.1 μM Compound: 2	Antiproliferative activity against rat VSMC assessed as cell growth inhibition Antiproliferative activity against rat VSMC assessed as cell growth inhibition	[PMID: 21401114]
VSMC	GI₅₀	95.14 μM Compound: 2	Growth inhibition against rat VSMC after 72 hrs by MTT assay Growth inhibition against rat VSMC after 72 hrs by MTT assay	[PMID: 21401114]

In Vitro

Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29^[1].
Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth^[1].
LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase^[1].
Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Proliferation Assay^[1]

View Protocol

Cell Line:

Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29
Concentration:

1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
Incubation Time:

72 hours
Result:

Inhibited the proliferation of four cell lines. The IC₅₀ ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116).

Cell Proliferation Assay^[1]

View Protocol

Cell Line:

Colorectal carcinoma cell lines LoVo
Concentration:

1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
Incubation Time:

24, 48, 72 hours
Result:

Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 μM induced 71.1±1.9 % growth inhibitions in LoVo cells.

Cell Cycle Analysis^[1]

View Protocol

Cell Line:

LoVo cells
Concentration:

0, 10, 20, 40, or 80 μM
Incubation Time:

24 hours
Result:

Exposure to 40.0 μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population.

Western Blot Analysis^[1]

View Protocol

Cell Line:

LoVo cells
Concentration:

10, 20, 40, or 80 μM
Incubation Time:

24 hours
Result:

Suppressed cyclin B1, cdc2 and cdc25c protein expression.

In Vivo

Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts^[1]
Dosage:

10, 30, or 50 mg/kg/day
Administration:

Gastrointestinal gavage; for 10 consecutive days
Result:

Showed inhibitory rates of 33.1 % and 45.3 % at doses of 30 and 50 mg/kg/day.

Chemical Information

CAS. Nr. 633-65-8
Appearance Solid
Molecular Weight 371.81
Formel C₂₀H₁₈ClNO₄
Color Light yellow to yellow
SMILES

COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
Synonyms

Natural Yellow 18 chloride
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (83)

All In Vivo Efficacy StudyBio/Physico-chemical AssayRT-PCRIFCell Imaging/StainingOthersWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Stem Cell

Vagal pathway activation links chronic stress to decline in intestinal stem cell function. [Abstract]

2025 Mar 20:S1934-5909(25)00084-0. PMID: 40120585
Nat Commun

Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation. [Abstract]

2025 Jan 2;16(1):212. PMID: 39747079

Berberine chloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):212. [Abstract]

A549 (1 ×10⁶) cells were subcutaneously inoculated into the right scruff of the female BALB/c nude mouse (n = 8/group). On day 22 after inoculation, mice were given Berberine (p.o.; 40 mg/kg; daily for 12 days) . The tumor volumes on indicated days after gavage were examined

Berberine chloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):212. [Abstract]

H1299 cells were treated with or without Berberine (Ber;5 μM; 24 h). Cells were subjected to qPCR (n = 3 independent experiments) analyses.
Acta Pharm Sin B

Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis. [Abstract]

2025 Sep;15(9):4789-4806. PMID: 41049740

Berberine chloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]

The hydroxyproline assay kit was used to detect the secretion of fibroblast collagen in NMCFs by Berberine (BBC; 70 μM）. n=3-4. *P< 0.05, **P< 0.01 vs. CTL #P<0.05, ###P <0.001 vs. TGF-β1.

Berberine chloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]

Immunofluorescence in determining the expression of P4HA1 after treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) in the heart tissue of MI mice. n=3. *P < 0.05, **P < 0.01 vs. Sham, #P < 0.05, ##P < 0.01 vs. MI. Scale bar, 200 µm.

Berberine chloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]

Echocardiographic detection of cardiac function changes in MI mice and treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) . n=3-4. *P < 0.05 vs. Sham, #P < 0.05 vs. MI.
Adv Sci (Weinh)

ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. [Abstract]

2026 Mar;13(16):e13310. PMID: 41589654
NPJ Biofilms Microbiomes

Berberine chloride hydrate impairs Streptococcus mutans biofilm formation via inhibiting sortase A activity. [Abstract]

2025 Jul 1;11(1):120. PMID: 40595693

Berberine chloride purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):120. [Abstract]

Effects of BH (Berberine chloride hydrate, 0-256 μg/mL) on living S. mutans free-floating bacterial cells by CFU counts.

Berberine chloride purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):120. [Abstract]

Effects of BH (Berberine chloride hydrate, 0-256 μg/mL) on metabolic activity of pre-established S. mutans biofilm on culture plates.

Berberine chloride purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):120. [Abstract]

BH (Berberine chloride hydrate) shows anti-biofilm formation effects on bovine enamel blocks.

Berberine chloride purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):120. [Abstract]

BH (Berberine chloride hydrate) shows anti-biofilm formation effects on bovine enamel blocks. Representative CLSM images of S. mutans biofilms on the bovine enamel.

Berberine chloride purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):120. [Abstract]

The inhibitory effect of BH (Berberine chloride hydrate, 16-256 μg/mL) on SrtA activity.
Phytomedicine

Berberine facilitates alveolar bone regeneration via Ptgs2-mediated dual regulation of osteoblast differentiation and fibroblast inhibition. [Abstract]

2026 Jan:150:157678. PMID: 41401587
Phytomedicine

Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer. [Abstract]

2025 Sep 4:148:157233. PMID: 40972261
Phytomedicine

Berberine protects against dysentery by targeting both Shigella filamentous temperature sensitive protein Z and host pyroptosis: Resolving in vitro-vivo effect discrepancy. [Abstract]

2025 Apr:139:156517. PMID: 39986228
Phytomedicine

Modified Hu-lu-ba-wan protects diabetic glomerular podocytes via promoting PKM2-mediated mitochondrial dynamic homeostasis. [Abstract]

2024 Jan:123:155247. PMID: 38128393
Phytomedicine

Berberine ameliorates iron levels and ferroptosis in the brain of 3 × Tg-AD mice. [Abstract]

2023 Sep:118:154962. PMID: 37506403
J Hazard Mater

Ammonia-induced exosomal miRNA disrupts autophagy and promotes lung injury: Therapeutic potential of natural compounds. [Abstract]

2026 Mar 15:506:141417. PMID: 41775203
Acta Pharmacol Sin

Tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy. [Abstract]

2023 Feb;44(2):332-344. PMID: 35948750
NPJ Sci Food

Network pharmacology study on the mechanism of berberine in Alzheimer's disease model. [Abstract]

2025 Feb 4;9(1):16. PMID: 39900946
Int J Biol Macromol

Berberine@AgNPs@Carboxylated chitosan hydrogel dressing with immunomodulatory and anti-biofilm properties promotes wound repair in drug-resistant bacterial infections. [Abstract]

2025 Jun;315(Pt 1):144496. PMID: 40409636
Int J Nanomedicine

Combined Therapy of Experimental Autoimmune Uveitis by a Dual-Drug Nanocomposite Formulation with Berberine and Dexamethasone. [Abstract]

2023 Jul 31:18:4347-4363. PMID: 37545873
Mol Med

Berberine promotes primordial follicle activation and increases ovulated oocyte quantity in aged mice. [Abstract]

2024 Dec 20;30(1):251. PMID: 39707173
Phytother Res

A Novel Mechanism of Berberine Targeting EIF2AK2 Dimerization Attenuates Methylglyoxal-Induced Endothelial Senescence and Apoptosis. [Abstract]

2026 Mar;40(3):887-906. PMID: 41520368
Free Radic Biol Med

Redox switch C674 in SERCA2 triggers Ca2+-calcineurin-MCU-Drp1 cascade and pulmonary vascular remodeling. [Abstract]

2025 Dec 16:244:380-394. PMID: 41412527
Chin Med

Berberine ameliorates high-fat diet-induced metabolic disorders through promoting gut Akkermansia and modulating bile acid metabolism. [Abstract]

2025 Nov 17;20(1):190. PMID: 41243097
J Ethnopharmacol

Jiao-tai-wan and its effective component-berberine improve diabetes and depressive disorder through the cAMP/PKA/CREB signaling pathway. [Abstract]

2024 Apr 24:324:117829. PMID: 38296172
JCI Insight

Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment. [Abstract]

2023 Jul 24;8(14):e166306. PMID: 37485875
J Ethnopharmacol

Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA. [Abstract]

2022 Mar 1:285:114786. PMID: 34763043
CNS Neurosci Ther

Berberine Alleviates Kainic Acid-Induced Acute Epileptic Seizures in Mice via Reshaping Gut Microbiota-Associated Lipid Metabolism. [Abstract]

2025 Feb;31(2):e70253. PMID: 39915895
Biochem Pharmacol

Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis. [Abstract]

2021 Jun:188:114576. PMID: 33930347
Mech Ageing Dev

AMPK alleviates oxidative stress‑induced premature senescence via inhibition of NF-κB/STAT3 axis-mediated positive feedback loop. [Abstract]

2020 Oct:191:111347. PMID: 32882228
Dent Mater

Injectable, regenerative and anti-infective PEGylated polyglycerol sebacate-modified calcium phosphate cements triggered by berberine and rhBMP-2 for oral bone defect repair. [Abstract]

2026 May;42(5):898-911. PMID: 41633879
Inflammopharmacology

Berberine mitigates diclofenac-induced intestinal mucosal mechanical barrier dysfunction through the restoration of autophagy by inhibiting exosome-mediated lncRNA H19. [Abstract]

2024 Aug;32(4):2525-2540. PMID: 38758516
Anal Chim Acta

2026 May 12;1412:345649.
Pharm Biol

Berberine decreases S100B generation to regulate gut vascular barrier permeability in mice with burn injury. [Abstract]

2024 Dec;62(1):53-61. PMID: 38108311
Hepatol Commun

Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway. [Abstract]

2024 Mar 29;8(4):e0405. PMID: 38573832
Int J Mol Sci

Berberine Alleviates Shigella-Induced Dysentery by Regulating Intestinal Barrier and Inflammatory Responses. [Abstract]

2026 Jan 21;27(2):1063. PMID: 41596706
Int Immunopharmacol

Berberine attenuates neuronal ferroptosis via the AMPK-NRF2-HO-1-signaling pathway in spinal cord-injured rats. [Abstract]

2024 Sep 24;142(Pt B):113227. PMID: 39321704
Int Immunopharmacol

Berberine enhances the function of intestinal stem cells in healthy and radiation-injured mice. [Abstract]

2024 Jul 30:136:112278. PMID: 38815353
Int Immunopharmacol

Berberine alleviates neuroinflammation by downregulating NFκB/LCN2 pathway in sepsis-associated encephalopathy: network pharmacology, bioinformatics, and experimental validation. [Abstract]

2024 May 30:133:112036. PMID: 38640713
Front Pharmacol

Berberine stimulates lysosomal AMPK independent of PEN2 and maintains cellular AMPK activity through inhibiting the dephosphorylation regulator UHRF1. [Abstract]

2023 Apr 18:14:1148611. PMID: 37144221
Molecules

Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies. [Abstract]

2024 May 14;29(10):2304. PMID: 38792165
Biochim Biophys Acta Mol Basis Dis

Berberine chloride alleviated intestinal inflammation and improved postoperative ileus by regulating macrophage polarization via PI3K/AKT signaling pathway. [Abstract]

2025 Oct;1871(7):167920. PMID: 40412730
Mol Med Rep

Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. [Abstract]

2023 Jan;27(1):17. PMID: 36453238
Sci Rep

Ursolic and oleanolic acids suppress MNNG induced malignant transformation of human gastric mucosal epithelium by regulating the PI3 K/AKT pathway. [Abstract]

2025 Jul 1;15(1):21623. PMID: 40594240
Sci Rep

Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation. [Abstract]

2022 Oct 17;12(1):17350. PMID: 36253427
J Cell Mol Med

Berberine Sensitises Breast Cancer Cells to Radiation via the Attenuation of DNA Ligase III. [Abstract]

2025 Sep;29(17):e70836. PMID: 40916080
Cell Signal

Inhibition of N6-methyladenosine methylation of ASC by berberine ameliorates pyroptosis of renal tubular epithelial cells in acute kidney injury. [Abstract]

2025 Jul:131:111732. PMID: 40074191
J Inflamm Res

Berberine Inhibits Acne-Related Lipid Secretion and Inflammation by Regulating the hsa-miR-3150a-3p/TP53 Pathway. [Abstract]

2025 Aug 21:18:11451-11461. PMID: 40860941
Aquacult Nutr

14 Jul 2022.
Aquaculture

15 May 2022, 738055.
Drug Dev Res

Polydatin Protects Against the Formation of PPE-Induced Abdominal Aortic Aneurysms in Mice by Activating Nuclear Factor Erythroid 2-Related Factor 2. [Abstract]

2026 Feb;87(1):e70223. PMID: 41486502
Fish Shellfish Immunol

Berberine inhibits SGIV replication by suppressing inflammatory response and oxidative stress. [Abstract]

2024 Jun:149:109522. PMID: 38548190
Microbiol Spectr

The inhibitory effect of berberine chloride hydrate on Streptococcus mutans biofilm formation at different pH values. [Abstract]

2023 Sep 25;11(5):e0217023. PMID: 37747238
Microb Pathog

Berberine inhibits Mycoplasma synoviae infection by suppressing PIK3CA-dependent inflammatory and apoptotic responses in avian macrophages. [Abstract]

2025 Dec:209:108114. PMID: 41115537
J Pharm Pharmacol

Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination. [Abstract]

2022 Sep 1;74(9):1353-1363. PMID: 35641094
Toxicol Appl Pharmacol

Berberine alleviates acute embolism-induced lung inflammation and injury by suppressing miR-22-5p expression and modulating the TLR4/NF-κB signaling pathway. [Abstract]

2025 Dec:505:117563. PMID: 40953642
Appl Biochem Biotechnol

Berberine Protects Against Dihydrotestosterone-Induced Human Ovarian Granulosa Cell Injury and Ferroptosis by Regulating the Circ_0097636/MiR-186-5p/SIRT3 Pathway. [Abstract]

2024 Aug;196(8):5265-5282. PMID: 38153651
Exp Cell Res

Berberine increases the killing effect of pirarubicin on HCC cells by inhibiting ATG4B-autophagy pathway. [Abstract]

2024 Jun 1;439(1):114094. PMID: 38750718
BMC Pharmacol Toxicol

Antitumor effects of erlotinib in combination with berberine in A431 cells. [Abstract]

2023 May 11;24(1):29. PMID: 37170144

Berberine chloride purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]

Berberine (BBR; 2.5, 5, 10 µM; 48 h) inhibits EGFR phosphorylation in a dose-dependent matter in A431cells.

Berberine chloride purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]

Berberine (BBR; 2.5 µM; 10 days) significantly inhibits NCI-H441 colony formation.

Berberine chloride purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]

Berberine (BBR; 0.625, 1.25, 2.5, 5, 10 µM; 48 h) inhibits the viability of A431cells in a dose-dependent matter.
Cardiovasc Drugs Ther

Berberine Reverses Nitroglycerin Tolerance through Suppressing Protein Kinase C Alpha Activity in Vascular Smooth Muscle Cells. [Abstract]

2022 Aug;36(4):633-643. PMID: 34319490
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Food Chem Toxicol

Berberine attenuates sunitinib-induced cardiac dysfunction by normalizing calcium regulation disorder via SGK1 activation. [Abstract]

2023 May:175:113743. PMID: 36972840
Tissue Cell

Overcoming osimertinib resistance in NSCLC: The role of Notch1 pathway inhibition by berberine. [Abstract]

2026 Jun:100:103365. PMID: 41687187
J Appl Toxicol

Berberine prevents against myocardial injury induced by acute β-adrenergic overactivation in rats. [Abstract]

2024 Nov;44(11):1700-1713. PMID: 38981847
Fitoterapia

2026 Sep:193:107388. PMID: 42476424
J Bone Miner Metab

Protective effects of berberine on senile osteoporosis in mice. [Abstract]

2021 Sep;39(5):748-756. PMID: 33829324
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
J Appl Microbiol

Enhanced in vitro antimicrobial activity of amphotericin B with berberine against dual-species biofilms of Candida albicans and Staphylococcus aureus. [Abstract]

2021 Apr;130(4):1154-1172. PMID: 32996236
Toxicol In Vitro

Inhibitory potential of phytochemicals on species-specific breast cancer resistance protein transport activity. [Abstract]

2025 Dec:109:106128. PMID: 40796067
Gene

Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress. [Abstract]

2022 Mar 30:816:146171. PMID: 35026293
Mol Reprod Dev

Effect of berberine combined with metformin on autophagy in polycystic ovary syndrome by regulating AMPK/AKT/mTOR pathway. [Abstract]

2024 Aug;91(8):e23768. PMID: 39155689
Arch Oral Biol

Investigating the mechanism of berberine in inhibiting periodontitis progression using machine learning, molecular docking, and experimental validation. [Abstract]

2026 Mar:183:106496. PMID: 41544413
J Food Biochem

2025 Jul 16.
Mol Genet Genomics

Berberine impedes the DNA damage repair to inhibit colorectal cancer by regulating the SOX17/TCF4/PIM3 axis. [Abstract]

2026 May 27;301(1):124. PMID: 42201413
Oncol Lett

Genome-wide CRISPR screening identifies CLDN1 as a central node in the anticancer mechanisms of berberine and as a therapeutic target in lung cancer. [Abstract]

2025 Dec 1;31(2):62. PMID: 41383979
Oncologie

2023 Mar 10.
Biol Pharm Bull

Berberine Encapsulated in Exosomes Derived from Platelet-Rich Plasma Promotes Chondrogenic Differentiation of the Bone Marrow Mesenchymal Stem Cells via the Wnt/β-Catenin Pathway. [Abstract]

2022 Oct 1;45(10):1444-1451. PMID: 35858798
Lett Drug Des Discov

2025 Dec 13.
bioRxiv

Mechanistic Language Modeling and Oxygenated 3D Screening Reveal Berberine and Enzalutamide Synergy in Resistant Prostate Cancer. [Abstract]

2026 Jan 26:2026.01.24.701539. PMID: 41659618
Res Sq

2025 Apr 15.
Genome Instab Dis

2025 Mar.
Biomed Pharmacother

Berberine exerts antidepressant effects in vivo and in vitro through the PI3K/AKT/CREB/BDNF signaling pathway. [Abstract]

2024 Jan:170:116012. PMID: 38113631
SSRN

2023 Jan 27.
Research Square Print

2022 Aug.
Research Square Preprint

2021 Sep.
Research Square Preprint

2021 Jun.
Research Square Preprint

2021 May.
Evid Based Complement Alternat Med

Effects of Berberine on Circular RNA Expression Profiles in Human Gastric Cancer Cells. [Abstract]

2021 May 4:2021:6688629. PMID: 34055022

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 8.33 mg/mL (22.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6895 mL

13.4477 mL

26.8955 mL

5 mM

0.5379 mL

2.6895 mL

5.3791 mL

10 mM

0.2690 mL

1.3448 mL

2.6895 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (3.36 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (3.36 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 11 mg/mL (29.59 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Cell Biology

ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68(1):53-62. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6895 mL	13.4477 mL	26.8955 mL	67.2386 mL
	5 mM	0.5379 mL	2.6895 mL	5.3791 mL	13.4477 mL
	10 mM	0.2690 mL	1.3448 mL	2.6895 mL	6.7239 mL
	15 mM	0.1793 mL	0.8965 mL	1.7930 mL	4.4826 mL
	20 mM	0.1345 mL	0.6724 mL	1.3448 mL	3.3619 mL

Bioz

Keywords

Berberine chloride

83 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Berberine chloride

Publications Citing Use of MedChemExpress (MCE) Berberine chloride

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen